July 2026
Neuroplasticity
What July 2026's 12 new studies found, synthesized from the papers below. All Neuroplasticity research →
The synthesis
Synthesized from 12 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Neuroplasticity, neural plasticity, brain plasticity, synaptic plasticity, neurogenesis, then ranked by relevance.
Research in July 2026 indicates that psychedelics and related compounds such as psilocybin, DMT, ketamine, and MDMA can engage neuroplastic mechanisms, including synaptic plasticity, dendritic signaling, and epigenetic changes, though effects are often context-dependent and evidence for clinical durability remains limited. Findings are consistent in showing that these agents modulate plasticity-related pathways, but the translation to lasting structural or functional outcomes is not yet firmly established.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Antidepressant-like effects of ketamine involve CX3CL1/CX3CR1 signaling-mediated synaptic plasticity in the mPFC 2026 | animal study | Supports | Ketamine reversed depression-like behaviors and enhanced synaptic plasticity, but blocking CX3CL1/CX3CR1 signaling prevented these effects, indicating the pathway is necessary for ketamine's antidepressant actions. | |
| Psychedelic drug action at dendrites is gated by behavioral state and serotonin receptors 2026 | experimental study | Supports | Psilocybin transiently increased dendritic calcium event rates in a brain state- and 5-HT2A receptor-dependent manner, but altered the predictive relationship between acute dendritic signaling and subsequent spine formation. | |
| Post-Perturbation Integrative Neuroplasticity (PPIN): A Descriptive Framework for Non-Pathological Cross-Domain Cognitive Reorganization 2026 | theoretical or philosophical paper | Unclear | Argues that a descriptive framework, Post-Perturbation Integrative Neuroplasticity, characterizes broad cross-domain cognitive reorganization following significant perturbations, distinguishing it from pathological conditions and post-traumatic growth. | |
| Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of Depression 2026 | review | Supports | Reviews evidence that ketamine and esketamine have the strongest evidence among rapid-acting antidepressants, while psilocybin-assisted therapy shows promise but remains investigational, highlighting the role of neuroplasticity in depression treatment. | |
| Psilocybin's effect on human brain synaptic plasticity. 2026 | observational cohort | 15 | Mixed | Psilocybin did not significantly increase synaptic density overall, but participants in a therapeutic-like setting showed greater increases in synaptic density and more intense mystical-type experiences than those in an MRI scanner. |
| Brain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA 2026 | clinical trial | 36 | Supports | Ketamine and MDMA induced peripheral DNA methylation changes converging on neuroplasticity and neuroimmune pathways, with hundreds of altered genes and functional networks. |
| Study 35070 | in vitro experimental study | Supports | Brief DMT exposure increased proliferation of human neural stem cells in a concentration-dependent manner and upregulated neurotrophin expression including BDNF. | |
| Treating addiction with an addictive drug: the ketamine paradox revisited 2026 | narrative review | Mixed | Ketamine combined with psychotherapy showed promising reductions in craving and increases in abstinent days for alcohol and cocaine use disorders, but effects on relapse prevention were inconsistent and misuse risk remains. | |
| Exploring neural underpinning of Christian faith: How far can we go? 2026 | theoretical or philosophical paper | Unclear | Argues that Christian commitment and practice may yield dedicated neural structures or networks over time and foster interplay with secular cognition, proposing hypotheses and methods to test this. | |
| Brain and Environment Interaction: Neuroplasticity of the Visual Cortex and the Roles of Sensory Deprivation, Sleep, and Dreams. 2026 | review | Supports | Reviews evidence that neuroplasticity in the adult visual cortex persists and can contribute to functional outcomes, with sleep and dreaming playing a mediating role. | |
| Combined Ketamine and Cognitive-Behavioral Therapy: Leveraging Metaplasticity to Enhance Treatment Outcomes 2026 | review | Supports | Reviews evidence that combining ketamine with cognitive-behavioral therapy may leverage ketamine-induced neuroplasticity and cognitive flexibility for enhanced and more durable antidepressant effects, but critical parameters remain undefined. | |
| A conceptual framework based on current and emerging treatments for treatment-resistant depression: mechanistic evolution, clinical evidence, and future directions. 2026 | review | Supports | Reviews evidence that treatment-resistant depression is conceptualized as impaired neural adaptability, with treatments like ketamine and neuromodulation representing a paradigm shift by reopening plasticity windows and recalibrating dysfunctional networks. |
Ketamine reversed depression-like behaviors and enhanced synaptic plasticity, but blocking CX3CL1/CX3CR1 signaling prevented these effects, indicating the pathway is necessary for ketamine's antidepressant actions.
animal study
Psilocybin transiently increased dendritic calcium event rates in a brain state- and 5-HT2A receptor-dependent manner, but altered the predictive relationship between acute dendritic signaling and subsequent spine formation.
experimental study
Argues that a descriptive framework, Post-Perturbation Integrative Neuroplasticity, characterizes broad cross-domain cognitive reorganization following significant perturbations, distinguishing it from pathological conditions and post-traumatic growth.
theoretical or philosophical paper
Reviews evidence that ketamine and esketamine have the strongest evidence among rapid-acting antidepressants, while psilocybin-assisted therapy shows promise but remains investigational, highlighting the role of neuroplasticity in depression treatment.
review
Psilocybin did not significantly increase synaptic density overall, but participants in a therapeutic-like setting showed greater increases in synaptic density and more intense mystical-type experiences than those in an MRI scanner.
observational cohort Sample size: 15
Ketamine and MDMA induced peripheral DNA methylation changes converging on neuroplasticity and neuroimmune pathways, with hundreds of altered genes and functional networks.
clinical trial Sample size: 36
Brief DMT exposure increased proliferation of human neural stem cells in a concentration-dependent manner and upregulated neurotrophin expression including BDNF.
in vitro experimental study
Ketamine combined with psychotherapy showed promising reductions in craving and increases in abstinent days for alcohol and cocaine use disorders, but effects on relapse prevention were inconsistent and misuse risk remains.
narrative review
Argues that Christian commitment and practice may yield dedicated neural structures or networks over time and foster interplay with secular cognition, proposing hypotheses and methods to test this.
theoretical or philosophical paper
Reviews evidence that neuroplasticity in the adult visual cortex persists and can contribute to functional outcomes, with sleep and dreaming playing a mediating role.
review
Reviews evidence that combining ketamine with cognitive-behavioral therapy may leverage ketamine-induced neuroplasticity and cognitive flexibility for enhanced and more durable antidepressant effects, but critical parameters remain undefined.
review
Reviews evidence that treatment-resistant depression is conceptualized as impaired neural adaptability, with treatments like ketamine and neuromodulation representing a paradigm shift by reopening plasticity windows and recalibrating dysfunctional networks.
review
Points of agreement
- Multiple studies indicate that psychedelics and related compounds (psilocybin, DMT, ketamine, MDMA) engage neuroplastic mechanisms, including synaptic plasticity, dendritic signaling, and epigenetic changes.
- Reviews consistently highlight the role of neuroplasticity in the therapeutic effects of rapid-acting antidepressants and psychedelics.
- The importance of environmental context and brain state in modulating neuroplastic effects is emphasized across studies.
Conflicts
- One study found no overall significant increase in synaptic density after psilocybin, while another found context-dependent increases, suggesting inconsistency in the magnitude of neuroplastic effects.
- The relationship between acute dendritic signaling and structural plasticity was altered by psilocybin, contrasting with the assumption that acute signaling directly predicts long-term changes.
Gaps
- Durability of neuroplastic changes and their translation to clinical outcomes remains unclear.
- Most studies are preclinical or small-scale; larger human trials are needed.
- Optimal dosing, timing, and combination strategies for leveraging neuroplasticity are not well-defined.
- The role of environmental context and brain state in neuroplastic effects requires further investigation.
- Long-term safety and misuse potential of compounds like ketamine and MDMA are not fully addressed.